Romania · Delayed Price · Currency is RON S.C. Ropharma Statistics
Total Valuation
S.C. Ropharma has a market cap or net worth of RON 105.32 million. The enterprise value is 248.10 million.
| Market Cap | 105.32M |
| Enterprise Value | 248.10M |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
S.C. Ropharma has 511.27 million shares outstanding. The number of shares has decreased by -16.82% in one year.
| Current Share Class | 511.27M |
| Shares Outstanding | 511.27M |
| Shares Change (YoY) | -16.82% |
| Shares Change (QoQ) | -24.69% |
| Owned by Insiders (%) | 23.69% |
| Owned by Institutions (%) | 10.78% |
| Float | 128.46M |
Valuation Ratios
The trailing PE ratio is 12.17.
| PE Ratio | 12.17 |
| Forward PE | n/a |
| PS Ratio | 0.06 |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | 2.63 |
| P/OCF Ratio | 2.05 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.14, with an EV/FCF ratio of 6.19.
| EV / Earnings | 30.59 |
| EV / Sales | 0.15 |
| EV / EBITDA | 5.14 |
| EV / EBIT | 11.84 |
| EV / FCF | 6.19 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.05 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 3.63 |
| Debt / FCF | 4.36 |
| Interest Coverage | 3.84 |
Financial Efficiency
Return on equity (ROE) is 3.71% and return on invested capital (ROIC) is 2.24%.
| Return on Equity (ROE) | 3.71% |
| Return on Assets (ROA) | 1.27% |
| Return on Invested Capital (ROIC) | 2.24% |
| Return on Capital Employed (ROCE) | 5.31% |
| Weighted Average Cost of Capital (WACC) | 3.12% |
| Revenue Per Employee | 1.32M |
| Profits Per Employee | 6,426 |
| Employee Count | 1,262 |
| Asset Turnover | 1.61 |
| Inventory Turnover | 5.43 |
Taxes
In the past 12 months, S.C. Ropharma has paid 13.10 million in taxes.
| Income Tax | 13.10M |
| Effective Tax Rate | 57.02% |
Stock Price Statistics
The stock price has increased by +21.18% in the last 52 weeks. The beta is 0.33, so S.C. Ropharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +21.18% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.20 |
| Relative Strength Index (RSI) | 37.41 |
| Average Volume (20 Days) | 80,645 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.C. Ropharma had revenue of RON 1.67 billion and earned 8.11 million in profits. Earnings per share was 0.02.
| Revenue | 1.67B |
| Gross Profit | 330.41M |
| Operating Income | 20.95M |
| Pretax Income | 22.96M |
| Net Income | 8.11M |
| EBITDA | 34.67M |
| EBIT | 20.95M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 46.72 million in cash and 174.83 million in debt, with a net cash position of -128.11 million or -0.25 per share.
| Cash & Cash Equivalents | 46.72M |
| Total Debt | 174.83M |
| Net Cash | -128.11M |
| Net Cash Per Share | -0.25 |
| Equity (Book Value) | 271.16M |
| Book Value Per Share | 0.50 |
| Working Capital | 33.33M |
Cash Flow
In the last 12 months, operating cash flow was 51.50 million and capital expenditures -11.38 million, giving a free cash flow of 40.11 million.
| Operating Cash Flow | 51.50M |
| Capital Expenditures | -11.38M |
| Depreciation & Amortization | 13.72M |
| Net Borrowing | -9.39M |
| Free Cash Flow | 40.11M |
| FCF Per Share | 0.08 |
Margins
Gross margin is 19.83%, with operating and profit margins of 1.26% and 0.49%.
| Gross Margin | 19.83% |
| Operating Margin | 1.26% |
| Pretax Margin | 1.38% |
| Profit Margin | 0.49% |
| EBITDA Margin | 2.08% |
| EBIT Margin | 1.26% |
| FCF Margin | 2.41% |
Dividends & Yields
S.C. Ropharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 16.82% |
| Shareholder Yield | 16.82% |
| Earnings Yield | 7.70% |
| FCF Yield | 38.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.C. Ropharma has an Altman Z-Score of 1.88 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.88 |
| Piotroski F-Score | 5 |